IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v39y2021i10d10.1007_s40273-021-01066-x.html
   My bibliography  Save this article

A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement

Author

Listed:
  • Jihyung Hong

    (Gachon University)

  • Eun-Young Bae

    (Gyeongsang National University)

Abstract

Pharmacoeconomic (PE) guidelines, first published in 2006 and later updated in 2011, were developed to guide the preparation and submission of PE data to the Health Insurance Review and Assessment Service (HIRA) for drug reimbursement decision making in South Korea. This study, which was conducted as part of a project for revision of the PE guideline, reviewed utility values used in the PE submissions processed at HIRA during 2014–2018 to identify aspects of the current guidelines that may need to be revisited. A total of 50 PE submissions were processed at HIRA over the 5 years. Of these, 47 submissions that used quality-adjusted life-years as an outcome measure were included in this review. Data were extracted from full copies of the manufacturer’s initial submissions and committee documents provided by HIRA. Of the 47 submissions, nearly half (n = 23, 48.9%) used published sources to obtain health state utility values, followed by direct methods using time trade-off (n = 7) or standard gamble (n = 2) and indirect methods with patient-level data using the EQ-5D-3L (n = 4) or the EQ-5D-5L (n = 2). Mapping, using the EQ-5D-3L as a target measure, was also adopted in six submissions, although it was somewhat unfavourably described in the guideline. Notably, 52.2% of the submissions with published sources took utility values from different sources for different health states defined in a single model. In addition, details of utility measurement methods or mapping functions taken from published sources were relatively poorly reported. Moreover, the preferences of the Korean general public, preferred by the guideline, were rarely reflected in the utility values used in submissions relying on published sources (95.7% for foreign values only/mixed) and mapping (66.7%). While most submissions with direct and indirect methods used domestic preference values, the former was occasionally criticised by assessment committees because of health state descriptions. This review highlights a considerable amount of inconsistency in the measurement of utility values used in the PE submissions during 2014–2018, indicating a strong need for methodological standardisation.

Suggested Citation

  • Jihyung Hong & Eun-Young Bae, 2021. "A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement," PharmacoEconomics, Springer, vol. 39(10), pages 1109-1121, October.
  • Handle: RePEc:spr:pharme:v:39:y:2021:i:10:d:10.1007_s40273-021-01066-x
    DOI: 10.1007/s40273-021-01066-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-021-01066-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-021-01066-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Tsuchiya, A & Brazier, J & McColl, E & Parkin, D, 2002. "Deriving preference-based single indices from non-preference based condition-specific instruments: converting AQLQ into EQ5D indices," MPRA Paper 29740, University Library of Munich, Germany.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Brazier, JE & Yang, Y & Tsuchiya, A, 2008. "A review of studies mapping (or cross walking) from non-preference based measures of health to generic preference-based measures," MPRA Paper 29808, University Library of Munich, Germany.
    2. Billingsley Kaambwa & Julie Ratcliffe, 2018. "Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People’s Quality of Life Brief Questionnaire (OPQoL-Brief) Scores," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(1), pages 39-54, February.
    3. Billingsley Kaambwa & Gang Chen & Julie Ratcliffe & Angelo Iezzi & Aimee Maxwell & Jeff Richardson, 2017. "Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs)," PharmacoEconomics, Springer, vol. 35(1), pages 111-124, January.
    4. Zafar Zafari & Mohsen Sadatsafavi & Carlo A Marra & Wenjia Chen & J Mark FitzGerald, 2016. "Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma," PLOS ONE, Public Library of Science, vol. 11(1), pages 1-15, January.
    5. Samer A. Kharroubi & Richard Edlin & David Meads & Chantelle Browne & Julia Brown & Christopher McCabe, 2015. "Use of Bayesian Markov Chain Monte Carlo Methods to Estimate EQ-5D Utility Scores from EORTC QLQ Data in Myeloma for Use in Cost-Effectiveness Analysis," Medical Decision Making, , vol. 35(3), pages 351-360, April.
    6. Jeff Round & Annie Hawton, 2017. "Statistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values," PharmacoEconomics - Open, Springer, vol. 1(4), pages 233-239, December.
    7. Donna Rowen & John Brazier & Aki Tsuchiya & Mónica Hernández Alava, 2012. "Valuing states from multiple measures on the same visual analogue sale: a feasibility study," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 715-729, June.
    8. Matthijs M. Versteegh & Annemieke Leunis & Jolanda J. Luime & Mike Boggild & Carin A. Uyl-de Groot & Elly A. Stolk, 2012. "Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D," Medical Decision Making, , vol. 32(4), pages 554-568, July.
    9. Matthew Franklin & Katherine Payne & Rachel A. Elliott, 2018. "Quantifying the Relationship between Capability and Health in Older People: Can’t Map, Won’t Map," Medical Decision Making, , vol. 38(1), pages 79-94, January.
    10. Kamran Khan & Stavros Petrou & Oliver Rivero-Arias & Stephen Walters & Spencer Boyle, 2014. "Mapping EQ-5D Utility Scores from the PedsQL™ Generic Core Scales," PharmacoEconomics, Springer, vol. 32(7), pages 693-706, July.
    11. Rowen, D & Brazier, J & Tsuchiya, A & Hernández, M & Ibbotson, R, 2009. "The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results," MPRA Paper 29841, University Library of Munich, Germany.
    12. John Brazier & Yaling Yang & Aki Tsuchiya & Donna Rowen, 2010. "A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 215-225, April.
    13. Yaling Yang & John E. Brazier & Aki Tsuchiya & Tracey A. Young, 2011. "Estimating a Preference-Based Index for a 5-Dimensional Health State Classification for Asthma Derived from the Asthma Quality of Life Questionnaire," Medical Decision Making, , vol. 31(2), pages 281-291, March.
    14. Nick Kontodimopoulos & Panagiotis Bozios & John Yfantopoulos & Dimitris Niakas, 2013. "Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 307-314, April.
    15. Christine Mpundu-Kaambwa & Gang Chen & Remo Russo & Katherine Stevens & Karin Dam Petersen & Julie Ratcliffe, 2017. "Mapping CHU9D Utility Scores from the PedsQLTM 4.0 SF-15," PharmacoEconomics, Springer, vol. 35(4), pages 453-467, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:39:y:2021:i:10:d:10.1007_s40273-021-01066-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.